Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes (Q42490547)

1 November 2017

title

Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes (English)

1 reference

1 November 2017

M Ebinger

1

1 reference

1 November 2017

D R Jehle

2

1 reference

1 November 2017

R D Fussgaenger

3

1 reference

1 November 2017

H C Fehmann

4

1 reference

1 November 2017

P M Jehle

5

1 reference

1 November 2017

publication date

1 July 2000

1 reference

American Journal of Physiology - Endocrinology and Metabolism

1 November 2017

published in

1 reference

1 November 2017

volume

279

1 reference

1 November 2017

issue

1

1 reference

1 November 2017

page(s)

E88-94

1 reference

Hamster preproglucagon contains the sequence of glucagon and two related peptides

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

New developments in the incretin concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

21 January 2018

Glucagon-Like Peptides

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Molecular and functional characterization of insulin receptors present on hamster glucagonoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Identification of functional insulin receptors on membranes from an insulin-producing cell line (RINm5F).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

High affinity binding sites for proinsulin in human IM-9 lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Proinsulin as a marker for the development of NIDDM in Japanese-American men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

The insulin receptor: structure, function, and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Signal transduction of PACAP and GLP-1 in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Is glucagon-like peptide 1 an incretin hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Characterization of Sp-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole- 3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

Complexity in biological signaling systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

A non-disruptive technique for loading calcium buffers and indicators into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152/AJPENDO.2000.279.1.E88

10.1152/AJPENDO.2000.279.1.E88

21 January 2018

Identifiers

DOI

0 references

1 reference